The project was divided into 5 work packages. The work described here covers all activities from the beginning of the project up to the last reporting period.
WP1 day-to-day project management and communication and dissemination activities: A data management plan and a quality assurance plan has been prepared. After the launch of the Sino-EU PerMed website in 2020, it has been regularly updated. A total of 5 newsletters were published jointly with IC2PerMed in English and Chinese. 21 press releases were published. A total of 5 annual General Assembly meetings were held. Every 2-4 weeks online consortium meetings were held. Information exchange with ICPerMed, ERAPerMed, IC2PerMed, EP PerMed and the EC has taken place. A communication and dissemination plan has been established and regularly updated. During the last period, an exploitation plan has been developed.
WP2 identification of stakeholdes and framework conditions: A mapping of publications and patents was carried out in 2020. Based on this mapping, an article was published. In addition, relevant stakeholders were identified. An SWOT-analysis to better promote and support China's participation in ICPerMed was carried out. Due to restrictions during the Corona pandemic, a delayed hybrid stakeholder workshop was held in 2022, followed by the publication of a Policy Brief on S&T. In 2023, the mapping was updated. Based on the new results, an online database was developed. A second paper was published in a preprint repository.
WP3 networking of Chinese stakeholders with ICPerMed and the exchange between R&I: During the first years of the project, an action plan and a travel grant scheme were developed. Due to the corona pandemic, travel between the two regions was not possible until 2023. Together with IC2PerMed, contacts with MoST were facilitated. As travel restrictions between Europe and China has been made easier in the spring of 2023, the prepartion of the Clover Leaf Tours started. The first Clover Leaf Tour invited Chinese researchers to visit institutions in Europe, the second delegation visit invited European researchers to visit institutions in China and the third visit focused on bringing ELSA experts to China. During the last visit, initial meetings were held with relevant organisations for joining ICPerMed.
WP4 knowledge hub: A Science and Technology Task Force and an ELSA Task Force were established with relevant experts from Europe and China. Three S&T workshops have been organised. Two online workshops and one hybrid workshop. Regular exchanges with the Sino-EU S&T Task Force. A workshop on ELSA was held in last year. A policy brief was published based on the discussions.
WP5 ethical aspects: In the first months, an assessment was carried out.
Key Results Dissemination and Exploitation strategy
Mapping Data Base
1.Communication/Dissemination activities before end of project e.g EURACTIV Media partnership, etc.
2.Implementation into EP PerMed
3.Upgrade of the mapping integration with data from the database ClinicalTrials.gov
S&T Policy Brief and ELSA Policy Brief
1.Communication activities before end of project e.g EURACTIV Media partnership, etc.
2.Implementation of Policy Briefs on the ICPerMed and EP PerMed websites
3.Publication of ELSA Policy Brief in public journal
4.Uptake recommendations into EP PerMed working groups
Established S&T contacts in China and Europe and to governmental organizations
1. Key Chinese stakeholders become members of scientific boards etc. of ICPerMed/EP PerMed.
2.Integration of a governmental organizations into ICPerMed/EP Permed
